| Hodgkin Lymphoma |
jRCT1080224013: Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma) |
|
|
| Completed | N/A | 250 | Japan | Opdivo (nivolumab) - BMS | Ono Pharmaceutical Co., Ltd. | Classical Hodgkin's lymphoma | | | | |
NCT00165425: Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation |
|
|
| Active, not recruiting | N/A | 210 | US | Echo/Stress Echo | Dana-Farber Cancer Institute, Brigham and Women's Hospital | Hodgkin's Disease | 10/07 | 12/25 | | |
NCT00647010: T-cell Recovery in Patients With Leukemia, Advanced Lymphoma, Myelodysplastic Syndrome, or Myeloproliferative Disorder Receiving Alemtuzumab and Undergoing Donor Stem Cell Transplant |
|
|
| Recruiting | N/A | 40 | US | alemtuzumab, cyclophosphamide, cytarabine, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, total-body irradiation | Baylor College of Medicine | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms | 12/12 | | | |
HL-MVD, NCT06235047: Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL |
|
|
| Completed | N/A | 60 | Europe | | Federico II University | Classic Hodgkin Lymphoma | 01/23 | 01/24 | | |
HL_PR/R-B, NCT06295211: Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study. |
|
|
| Completed | N/A | 32 | NA | observational | Federico II University | Hodgkin Lymphoma | 09/23 | 02/24 | | |
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant. |
|
|
| No Longer Available | N/A | | US | Plerixafor, AMD3100, Mozobil | Genzyme, a Sanofi Company | Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma | | | | |
| Recruiting | N/A | 550 | RoW | | Claudio Gustavo Stefanoff, Adriana Alves de Souza Scheliga, Claudete Esteves Nogueira Pinto Klumb, Ricardo de Sá Bigni, Luciana Wernersbach Pinto, Rocio Hassan, Isabele Avila Small, Monik Mariano Pinto, Cecilia Ferreira da Silva | Lymphoma | 12/18 | 12/25 | | |
NCT03546101: Early Detection of Epstein-Barr Virus Related Disease. |
|
|
| Completed | N/A | 1527 | Europe | | University of Aarhus, Aarhus University Hospital | Post-transplant Lymphoproliferative Disorder, Mononucleosis, Epstein-Barr Virus Infections, Epstein-Barr Virus Related Malignancy, Epstein-Barr Viraemia, Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, Hemophagocytic Lymphohistiocytoses, Hemophagocytosis | 03/19 | 05/23 | | |
ChiCTR1800020067: National childhood and adolescent lymphoma cooperative group (China-Net Childhood Lymphoma, CNCL) multicenter study |
|
|
| Recruiting | N/A | 800 | | CNCL-NHL-Mature B cell lymphoma protocol ;CNCL-NHL-LBL protocol ;CNCL-NHL-ALCL protocol ;CNCL-HL protocol | Capital Medical University Beijing Children's Hospital; Capital Medical University Beijing Children’s Hospital, None | Childhood and adolescent lymphoma | | | | |
ChiCTR1800019618: Clinical study of tumor-associated antigen-specific T cells in the treatment of hematological malignancies |
|
|
| Not yet recruiting | N/A | 60 | | Cell transfusion | The first affliated hospital of USTC (Anhui provincial hospital); Anhui Anke Biotechnology (Group) Co., Ltd., Self-financing | Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome | | | | |
NCT03910283: Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer |
|
|
| Not yet recruiting | N/A | 120 | US | Cancer Mindset Intervention | Stanford University, National Center for Complementary and Integrative Health (NCCIH) | Cancer, Breast, Cancer, Lung, Cancer of Colon, Cancer of Rectum, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Hodgkin, Lymphoma, Low-Grade, Lymphoma, Mantle-Cell, Lymphoma, T-Cell | 09/20 | 12/20 | | |
NCT01196208 / 2010-020363-21: A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 |
|
|
| No Longer Available | N/A | | Europe, US, RoW | brentuximab vedotin, SGN-35 | Seagen Inc., Millennium Pharmaceuticals, Inc. | Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous | | | | |
| Recruiting | N/A | 12 | Europe | Immune checkpoint inhibitor, radiotherapy | Ospedale Maggiore Di Trieste | Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy | 09/20 | 09/20 | | |
NCT03838627: Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR) |
|
|
| Completed | N/A | 34 | US | | St. Jude Children's Research Hospital | Hodgkin Disease | 01/21 | 06/23 | | |
ChiCTR2100045957: 18F-FDG-PET/CT radiomic features in Hodgkin lymphoma are predictive of outcome |
|
|
| Recruiting | N/A | | | | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, National Natural Science Foundation of China (81601522), Medical Youth Talent Project of Jiangsu Province (QNRC2016749), Gusu Health Talent Program (GSWS2020013) | Hodgkin lymphoma | | | | |
ChiCTR1900025232: PD-1 blockade combined with bortezomib compared to single PD-1 blockade in the treatment of relapsed or refractory classical Hodgkin's lymphoma: a prospective cohort study |
|
|
| Not yet recruiting | N/A | 26 | | PD-1 blockade ;PD-1 blockade combined with bortezomib | West China Hospital, Sichuan University; Level of the institution：, None | relapsed or refractoryHodgkin's lymphoma | | | | |
| Recruiting | N/A | 275 | Europe | No intervention | Erasme University Hospital, Queen Fabiola Children's University Hospital | Fertility Preservation, Lymphoma, Pediatrics Cancer, Gonadotropin-releasing Hormone Agonist | 12/21 | 12/36 | | |
| Recruiting | N/A | 50 | | Car-T cells | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan Bio –Raid Biotechnology Co.Ltd | CD30+ Lymphoproliferative diseases | | | | |
| Recruiting | N/A | 500 | RoW | | Interni hematologicka klinika FNKV, Charles University, Czech Republic, General University Hospital, Prague, University Hospital Olomouc, University Hospital Hradec Kralove, University Hospital, Motol | Prognostic Cancer Model | 12/23 | 12/27 | | |
| Recruiting | N/A | 20 | | Anti-CD30 CAR-T | Beijing Boren Hospital; Beijing Boren Hospital, company | CD30+ lymphoproliferative disease | | | | |
NCT03200977: Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab |
|
|
| Active, not recruiting | N/A | 95 | US | Non-Interventional | Bristol-Myers Squibb | Lymphoma | 06/22 | 12/22 | | |
NCT04893538: Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 100 | RoW | First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9, First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9 | Tishreen University | Hodgkin Lymphoma | 06/22 | 07/22 | | |
ICIPRESIST19, NCT04025424: Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) |
|
|
| Recruiting | N/A | 350 | RoW | Genetic tests of the available tumor and plasma samples | Russian Academy of Medical Sciences | Melanoma, Squamous Cell Lung Cancer, Uveal Melanoma, Hodgkin Lymphoma | 06/22 | 12/23 | | |
NCT04748185: Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies |
|
|
| Completed | N/A | 358 | US | | Mayo Clinic | Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma | 07/22 | 07/22 | | |
NCT04986189: Lung Screening in People Cured of Hodgkin Lymphoma |
|
|
| Enrolling by invitation | N/A | 200 | Europe | Low dose CT thorax | The Christie NHS Foundation Trust, University of Manchester | Hodgkin Lymphoma, Lung Cancer | 10/22 | 10/22 | | |
NCT04636255: Physical Capacity in Hodgkin Lymphoma Survivors |
|
|
| Recruiting | N/A | 40 | RoW | Physical Characteristics, Assessment of Heart rate variability, Blood Pressure and Cardiac Autonomic Control, Evaluation of Baroreflex Control, Cardiac Function and Structure, Assessment of Coronary Anatomy and Calcium Score, Blood Assessments, Physical Capacity, Physical Training | University of Sao Paulo General Hospital | Hodgkin Lymphoma, Adult, Cardiovascular Diseases, Radiation Effect, Chemotherapy Effect | 10/22 | 10/23 | | |
| Completed | N/A | 592 | Europe | | University Hospital Southampton NHS Foundation Trust | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant Hodgkin Lymphoma, Peripheral T-cell Lymphoma | 10/22 | 01/24 | | |
NCT02589548: Brazilian Prospective Hodgkin Lymphoma Registry |
|
|
| Recruiting | N/A | 1400 | RoW | | Universidade Federal do Rio de Janeiro | Hodgkin Lymphoma, Hodgkin Disease | 12/22 | 12/22 | | |
| Completed | N/A | 120 | Europe | | The Lymphoma Academic Research Organisation | Hodgkin Lymphoma, B-Cell Lymphoma | 12/22 | 12/22 | | |
| Recruiting | N/A | 2200 | RoW | Radiotherapy:, Vincristine, Etoposide, Prednisone, Doxorubicin, Dacarbazine, Cyclophosphamide | GALIA AVRAHAMI, University of Giessen | Classical Hodgkins Lymphoma in Children and Adolescents. | 12/22 | 12/27 | | |
NCT01793233: Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas |
|
|
| Active, not recruiting | N/A | 203 | Canada, US | Laboratory Biomarker Analysis, Questionnaire Administration | Children's Oncology Group, National Cancer Institute (NCI) | Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma, Lymphoma | 12/22 | 12/24 | | |
HEART, NCT01790152: Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment |
|
|
| Recruiting | N/A | 420 | Canada, US, RoW | Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | Children's Oncology Group, National Cancer Institute (NCI) | Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm | 12/22 | 12/25 | | |
| Recruiting | N/A | 28 | Europe | Exercise | Turku University Hospital | Tumor | 12/22 | 12/22 | | |
ChiCTR2100050633: Family management interventions in children with malignant tumors of different types of family management construction and application of the programme |
|
|
| Recruiting | N/A | 44 | | WeChat small program intervention | Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University, Chongqing Science and Health Joint Medical Research Project | children's malignant tumor | | | | |
REVOLUMHOD, NCT04621604: Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma. |
|
|
| Terminated | N/A | 7 | Europe | blood samples | Rennes University Hospital | Hodgkin Lymphoma | 01/23 | 10/23 | | |
| Completed | N/A | 124 | Europe | RITA (App) | Advice Pharma Group srl | Multiple Myeloma, Solitary Plasmacytoma, Amyloidosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma, Lymphocytic Lymphoma, Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplasia, Chronic Myeloproliferative Disorder, Treatment Adherence, Treatment Adherence and Compliance | 01/23 | 01/23 | | |
NCT03117036: Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III |
|
|
| Recruiting | N/A | 600 | RoW | Chemotherapy, Treatment | Samsung Medical Center, Samsung Genomic Institute | Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin | 12/24 | 12/26 | | |
eHOPE, NCT05455268: Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma Parents |
|
|
| Completed | N/A | 51 | RoW | eHOPE, Usual care | Universiti Kebangsaan Malaysia Medical Centre, Universiti Putra Malaysia, Ministry of Health, Malaysia | Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Pediatric Non-Hodgkin Lymphoma, Pediatric Hodgkin Lymphoma | 03/23 | 03/23 | | |
NCT04776265: RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT |
|
|
| Recruiting | N/A | 100 | RoW | Evaluation of therapeutical approach after ASCT | Grupo Argentino de Tratamiento de la Leucemia Aguda, Takeda | Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma | 03/24 | 04/24 | | |
NCI-2021-10994, NCT05169151: Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study |
|
|
| Withdrawn | N/A | 500 | US | Smartphone Application, App, Smartphone App | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Central Nervous System Neoplasm, Hodgkin Lymphoma, Malignant Solid Neoplasm, Non-Hodgkin Lymphoma, Sarcoma | 04/23 | 04/23 | | |
ChiCTR2100053662: An open label, single center, single arm clinical study for infusion of anti-CD30 CAR-T therapy following autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed, refractory and high-risk CD30-positive lymphoproliferative disorders |
|
|
| Recruiting | N/A | 30 | | Chimeric Antigen Receptor T-Cell Immunotherapy | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Bio –Raid Biotechnology Co.,Ltd. | CD30-positive lymphoproliferative disorders | | | | |
| Recruiting | N/A | 300 | RoW | | Innovent Biologics (Suzhou) Co. Ltd. | Relapsed or Refractory Classical Hodgkin's Lymphoma | 06/23 | 12/23 | | |
NCT06203652: The Pathogenesis and Prognostic Factors of Lymphoma |
|
|
| Recruiting | N/A | 2000 | RoW | Real-world regimen | Shanghai Zhongshan Hospital | Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma | 12/27 | 12/28 | | |
LY-SET-HAPLO, NCT03079089: Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders |
|
|
| Active, not recruiting | N/A | 40 | Europe | Sequential Packaging (SET), Transfusion graft, Prevention of GVHD, Care supports, Lymphocyte injection of prophylactic donor (PDLI) | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | Refractory or Relapsed Lymphoid Haemopathy | 07/23 | 07/23 | | |
NCT05813132: BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation |
|
|
| Completed | N/A | 60 | RoW | BEAM Protocol, (Bendamustine, Etoposide, Cytarabine, Melphalan, CEM protocol, (Carboplatin, Etoposide, Melphalan) | Rehab Werida | Lymphoma | 09/23 | 12/23 | | |
NCT04213209: Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" |
|
|
| Completed | N/A | 95 | Japan | Brentuximab Vedotin (Genetical Recombination), ADCETRIS Intravenous Infusion 50 mg | Takeda | Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma | 12/23 | 12/23 | | |
NCT00039676: Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer |
|
|
| Active, not recruiting | N/A | 1836 | US | | National Cancer Institute (NCI) | Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease | | | | |
| Enrolling by invitation | N/A | 550 | US | | National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), Non-Hodgkins Lymphoma, Acute Myelogenous Leukemia, Hodgkins Lymphoma | | | | |
ChiCTR2000028922: CD19 and CD30 CAR-T Cells Immunotherapy for Relapsing/Refractory Hodgkin’s Lymphoma Patients: single center, single arm, open clinical study |
|
|
| Recruiting | N/A | 8 | | CD19 and CD30 CAR-T cells combined in the treatment | The Third Affiliated Hospital of Kunming Medical University; The Third Affiliated Hospital of Kunming Medical University, The hospital raised funds by itself | Hodgkin's lymphoma | | | | |
NCT04665063: A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma |
|
|
| Recruiting | N/A | 20 | RoW | Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis | Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital | Hodgkin's Lymphoma | 10/23 | 10/25 | | |
| Recruiting | N/A | 650 | US, RoW | | National Cancer Institute (NCI) | Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis, Leukemia-Lymphoma, Adult T-Cell | | | | |
NCT06131801: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution |
|
|
| Recruiting | N/A | 30 | US | 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. | Children's Hospital Medical Center, Cincinnati | Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma | 12/26 | 12/27 | | |
NCT00582621: Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders |
|
|
| Recruiting | N/A | 500 | US | | Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, St. Jude Children's Research Hospital | Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer | 12/25 | 12/25 | | |
NCT01890486: The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen |
|
|
| Recruiting | N/A | 2000 | US | | Wake Forest University Health Sciences | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases | 12/25 | 12/25 | | |
NCT05019976: Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 30 | US | Radiation - Dose Level 0, Radiation - Dose Level 1, Radiation - Dose Level 2, Radiation - Dose Level 3, Radiation - Dose Level 4 | University of Chicago | Non-hodgkin Lymphoma, Hodgkin Lymphoma, Lymphoma | 12/27 | 12/27 | | |
DETECT, NCT04892667: Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG |
|
|
| Recruiting | N/A | 484 | Europe | intervention | Assistance Publique - Hôpitaux de Paris | Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin | 12/23 | 10/24 | | |
NCT05972577: Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study |
|
|
| Active, not recruiting | N/A | 30 | US | Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | Ohio State University Comprehensive Cancer Center | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma | 12/23 | 12/24 | | |
NCT05205512: Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial |
|
|
| Active, not recruiting | N/A | 10 | US | Exercise Intervention, Questionnaire Administration, Telemedicine, Telehealth | City of Hope Medical Center, National Cancer Institute (NCI) | Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 10/24 | 10/24 | | |
LYMPHOLD, NCT05101759: Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy |
|
|
| Recruiting | N/A | 100 | Europe | Comprehensive Geriatric Assessment | University Hospital, Toulouse, Institut Claudius Regaud | Neoplasm, Plasma Cell, Lymphoma | 12/24 | 12/24 | | |
NCT04072393: Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers |
|
|
| Recruiting | N/A | 25 | US | Home-based cardiac rehabilitation | Washington University School of Medicine, The Foundation for Barnes-Jewish Hospital | Lung Cancer, Esophageal Cancer, Thoracic Cancer, Hodgkin Lymphoma, Hodgkin Disease, Non-hodgkin Lymphoma, Sarcoma, Thymoma, Breast Cancer | 03/25 | 03/25 | | |
| Recruiting | N/A | 74 | US | Interview with Clinicians, Field Test of UPLYFT with Lymphoma Survivors, Pilot of UPLYFT with Lymphoma Survivors | Dana-Farber Cancer Institute, American Society of Hematology | Lymphoma, Survivorship | 01/25 | 04/25 | | |
NCT01788839: Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma |
|
|
| Recruiting | N/A | 400 | US | surveys, Blood draw, Transvaginal ultrasounds | Memorial Sloan Kettering Cancer Center | Breast Cancer, Lymphoma, Hodgkin's Lymphoma | 02/25 | 02/25 | | |
NCT03361020: Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation |
|
|
| Active, not recruiting | N/A | 434 | US | | St. Jude Children's Research Hospital, National Cancer Institute (NCI), University of California, San Diego | Obstructive Sleep Apnea, Hodgkin Lymphoma | 07/23 | 07/28 | | |
NCT05254821: Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients |
|
|
| Recruiting | N/A | 130 | Europe | | Federico II University | Hodgkin Lymphoma | 02/24 | 02/26 | | |
| Completed | N/A | 84 | US | observation only | Abramson Cancer Center at Penn Medicine | Leukemia, Myeloid, Acute, Leukemia, Lymphoid, Acute, Cardiotoxicity | 05/24 | 05/24 | | |
| Recruiting | N/A | 60 | US | AYA Connect intervention, Positive Psychology (PP) intervention, Positive Psychology Plus (PP+) intervention | UNC Lineberger Comprehensive Cancer Center | Cancer, Physical Activity, Cancer Survivorship, Mental Health, Obesity, Breast Cancer, Breast Neoplasms, Malignant Neoplasm, Hodgkin Lymphoma, Hodgkin Disease, Non Hodgkin Lymphoma, Lymph Node Cancer, Nasopharyngeal Carcinoma, Sarcoma, Ewing Sarcoma, Chondrosarcoma, Osteoid Sarcoma, Myeloma, Leukemia, Bone Tumor, Brain Tumor, Central Nervous System Tumor, Germ Cell Tumor | 11/24 | 11/24 | | |
AH-HA, NCT03935282: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors |
|
|
| Active, not recruiting | N/A | 645 | US | AH-HA Tool in the EPIC EHR | Wake Forest University Health Sciences, National Cancer Institute (NCI), Washington University School of Medicine, University of Texas Southwestern Medical Center | Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms, Hodgkin Disease, Non Hodgkin Lymphoma | 03/25 | 03/25 | | |
NCT02106611: Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors |
|
|
| Active, not recruiting | N/A | 133 | US | Clinical Assessment, Stress cardiac MRI, Stress echocardiogram | Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University | Hodgkin Lymphoma Survivor | 04/25 | 04/25 | | |
NCT06340243: Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt |
|
|
| Not yet recruiting | N/A | 50 | NA | radiotherapy | Assiut University | Pediatric Hodgkin Lymphoma | 04/26 | 04/26 | | |
| Recruiting | N/A | 350 | US | Bioelectric Impedance Analysis, BIA, Bioelectric Impedance, Bioelectric Impedance Test, Bioelectrical Impedance Analysis, Bioimpedance Analysis, Biospecimen Collection, Cardiopulmonary Exercise Testing, CPET, CPX, Echocardiography, Physical Performance Testing, Physical Fitness Testing, Physical Function Testing, Pulmonary Function Test, lung function test, PFT, Pulmonary Function Testing, Pulmonary Function Tests, Questionnaire Administration, Ultrasound | City of Hope Medical Center, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI) | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma | 12/24 | 12/24 | | |
NCT06363201: Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours |
|
|
| Not yet recruiting | N/A | 40 | RoW | Ocoxin Oral solution | Catalysis SL | Advanced Cancer, Advanced Solid Tumor, Lymphoma, Hodgkin, Central Nervous System Tumor, Sarcoma, Germ Cell Tumor, Pediatric Cancer | 12/24 | 12/25 | | |
| Not yet recruiting | N/A | 18 | NA | CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version) | Miltenyi Biomedicine GmbH, City of Hope Comprehensive Cancer Center | Hematological Malignancies | 04/27 | 04/27 | | |
NCT06421987: Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors |
|
|
| Recruiting | N/A | 100 | US | Near Infrared Spectroscopy (NIRS) | St. Jude Children's Research Hospital | Hodgkin Lymphoma, Adult | 03/26 | 03/27 | | |
PRIMAL, NCT05135351: Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation |
|
|
| Recruiting | N/A | 30 | US | Resistant Starch, Maltodextrin | University of Nebraska | Multiple Myeloma, Lymphoma | 07/26 | 07/26 | | |
CTRL-ALT-D, NCT03904134: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) |
|
|
| Active, not recruiting | N/A | 1753 | US | Donor Search Prognosis Score | Center for International Blood and Marrow Transplant Research, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program, Medical College of Wisconsin | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease | 06/24 | 03/25 | | |
NCT05550948: Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer |
|
|
| Recruiting | N/A | 30 | US | Transcranial photobiomodulation (tPBM) - Mobile System, Vielight portable tPBM NeURO device. | St. Jude Children's Research Hospital | ALL, Hodgkin Lymphoma, Cancer, Survivorship | 06/24 | 02/25 | | |
BELIEVE, NCT04998331: A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin |
|
|
| Active, not recruiting | N/A | 51 | Europe | No Intervention | Takeda | Hodgkin Disease, Lymphoma, T-Cell, Cutaneous | 06/24 | 06/24 | | |
ChiCTR2100053504: An exploratory clinical study to evaluate the safety and efficacy of anti-CD30 CAR T cell injection (anti CD30 CAR T cells) in patients with CD30+ relapsed/refractory lymphoma |
|
|
| Recruiting | N/A | 12 | | Infusion anti CD30 CAR T cells | Tongji Hospital of Tongji University; Tongji Hospital of Tongji University, Shanghai First Song Therapeutics Co., LTD. | CD30+ relapsed/refractory lymphoma | | | | |
| Recruiting | N/A | 8 | Europe | Positron emission tomography (PET) imaging at rest and during supine bicycle exercise | Turku University Hospital | Tumor Blood Flow at Rest and During Exercise | 08/24 | 08/24 | | |
| Recruiting | N/A | 300 | Europe | | Rotkreuzklinikum München gGmbH | AIDS Related Lymphoma, HIV Related Lymphoma | 08/24 | 08/29 | | |
NCT04053439: Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications |
|
|
| Recruiting | N/A | 188 | Canada | Blood test for determination of CHIP | Sunnybrook Health Sciences Centre, The Leukemia and Lymphoma Society, Queen's University | Lymphoma, Chemotherapeutic Toxicity | 09/24 | 09/26 | | |
ChiCTR2100053505: An exploratory clinical study to evaluate the safety and efficacy of anti-CD30 CAR T cell injection (anti CD30 CAR T cells) in patients with CD30+ relapsed/refractory lymphoma |
|
|
| Recruiting | N/A | 12 | | Infusion anti CD30 CAR T cells | Hubei Cancer Hospital; Hubei Cancer Hospital, Shanghai First Song Therapeutics Co., LTD. | CD30+ relapsed/refractory lymphoma | | | | |
| Recruiting | N/A | 42 | Europe | Resistance Exercise Training | Rigshospitalet, Denmark | Lymphoma, B-Cell, Lymphoma, Hodgkin, Exercise, Body Composition, Physical Functional Performance, Quality of Life, Sarcopenia, Muscle, Skeletal, Patient Reported Outcome Measures | 10/24 | 01/25 | | |
MinimALL, NCT06093334: Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD |
|
|
| Recruiting | N/A | 50 | Europe | Low-field magnetic resonance imaging, Cardiopulmonary testing, Pulmonary testing, Blood sample | University of Erlangen-Nürnberg Medical School | Acute Lymphoblastic Leukemia, Hodgkin Disease, Allogeneic Stem Cell Transplantation | 10/24 | 12/24 | | |
NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone |
|
|
| Withdrawn | N/A | 200 | RoW | No Intervention | Takeda | Hodgkin Lymphoma | 10/24 | 10/24 | | |
NCT01483664: Communication Skills Intervention to Promote Transition Into Survivorship |
|
|
| Active, not recruiting | N/A | 314 | US | | Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, Maimonides Medical Center, H. Lee Moffitt Cancer Center and Research Institute, Rutgers University, Tampa General Hospital, University of California, Los Angeles, National Cancer Institute (NCI), Monash University, Weill Cornell Medical College in Qatar, New York Presbyterian Brooklyn Methodist Hospital, San Francisco State University | Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma | 11/24 | 11/24 | | |
ChiCTR2200056525: An exploratory clinical study to evaluate the safety and efficacy of anti CD30 CAR T cell injection (anti CD30 CAR T cells) in patients with CD30+relapsed/refractory lymphoma |
|
|
| Not yet recruiting | N/A | 12 | | Infusion of anti CD30 CAR T cells | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Shanghai First Song Therapeutics Co., LTD. | CD30+ relapsed/refractory lymphoma | | | | |
NCT05780554: Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg/kg |
|
|
| Enrolling by invitation | N/A | 42 | RoW | Cyclophosphamide | Centro de Hematología y Medicina Interna | Graft Vs Host Disease | 03/25 | 03/25 | | |
| Recruiting | N/A | 380 | Europe | Sport Therapy, Precision exercise program | University of Milano Bicocca, Comitato Maria Letizia Verga,Italy | Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin, Drepanocytosis, Thalassemia Major, Adrenoleukodystrophy | 04/25 | 04/26 | | |
| Recruiting | N/A | 120 | US | LIFE-L Mediterranean Diet, LIFE-L Home-Based Exercise Program, Supportive Materials | University of Miami | Non Hodgkin Lymphoma, Hodgkin Lymphoma | 04/25 | 04/25 | | |
NCT01758042: Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders |
|
|
| Recruiting | N/A | 10 | US | Haploidentical Bone Marrow/Kidney | Massachusetts General Hospital | Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia | 07/25 | 07/27 | | |
PALS, NCT05595577: Improving Exercise Capacity With a Tailored Physical Activity Intervention |
|
|
| Recruiting | N/A | 100 | US | Exercise with Trainerize application, Cardiopulmonary exercise testing, MRI scan, Quality of Life Questionnaires, Cognitive and Brain Function Questionnaires, Blood draws | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma, Quality of Life, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer | 09/25 | 09/25 | | |
NCT02682667: Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols |
|
|
| Recruiting | N/A | 500 | US | | National Cancer Institute (NCI) | Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer | 12/25 | 12/27 | | |
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis |
|
|
| Recruiting | N/A | 400 | Europe | Treatment for clinical practise | Fondazione Italiana Linfomi ONLUS | Classical Hodgkin Lymphoma | 01/26 | 01/26 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
NCT01868451: Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma |
|
|
| Active, not recruiting | N/A | 118 | US | Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT) | Memorial Sloan Kettering Cancer Center, Seagen Inc., University of Rochester, City of Hope Medical Center, Stanford University | Hodgkin Lymphoma | 05/26 | 05/26 | | |
| Not yet recruiting | N/A | 748 | NA | Coronary CT | Baker Heart and Diabetes Institute, Western Health, Australia, Northern Hospital, Australia, Menzies Institute for Medical Research, Peter MacCallum Cancer Centre, Australia, The Alfred | Coronary Artery Disease | 05/26 | 05/26 | | |
| Recruiting | N/A | 70 | Europe | No Intervention | Takeda | Hodgkin Lymphoma | 06/26 | 06/26 | | |
NCT06098430: Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) |
|
|
| Recruiting | N/A | 100 | US | | St. Jude Children's Research Hospital | Nodular Lymphocyte-Predominant Hodgkin Lymphoma | 12/26 | 01/28 | | |
| Recruiting | N/A | 6000 | Europe | Patient registry | A.O. Ospedale Papa Giovanni XXIII | Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloma | 03/27 | 03/37 | | |
